BACKGROUND: In 2009 the declaration by the World Health Organization of a global pandemic of influenza-H1N1 virus led to a vaccination campaign to ensure protection for immunocompromised patients. The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies. DESIGN AND METHODS: We evaluated humoral and cellular immune responses to 2009 H1N1 vaccine in 97 adults with hematologic malignancies and compared these responses with those in 25 adult controls. Patients received two injections of vaccine 21 days apart and the controls received one dose. Antibody titers were measured using a hemagglutination-inhibition assay on days 0, 21 and 49 after injection of the first dose. Cellular immune responses to H1N1 were determined on days 0 and 49. RESULTS: By day 21 post-vaccination, protective antibody titers of 1:32 or more were seen in 100% of controls compared to 39% of patients with B-cell malignancies (P<0.001), 46% of allogeneic stem cell transplant recipients (P<0.001) and 85% of patients with chronic myeloid leukemia (P=0.086). After a second dose, seroprotection rates increased to 68%, (P=0.008), 73%, (P=0.031), and 95% (P=0.5) in patients with B-cell malignancies, after allogeneic stem cell transplantation and with chronic myeloid leukemia, respectively. On the other hand, T-cell responses to H1N1 vaccine were not significantly different between patients and controls. CONCLUSIONS: These data demonstrate the efficacy of H1N1 vaccine in most patients with hematologic malignancies and support the recommendation for the administration of two doses of vaccine in immunocompromised patients. These results may contribute towards the development of evidence-based guidelines for influenza vaccination in such patients in the future.
BACKGROUND: In 2009 the declaration by the World Health Organization of a global pandemic of influenza-H1N1 virus led to a vaccination campaign to ensure protection for immunocompromised patients. The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies. DESIGN AND METHODS: We evaluated humoral and cellular immune responses to 2009 H1N1 vaccine in 97 adults with hematologic malignancies and compared these responses with those in 25 adult controls. Patients received two injections of vaccine 21 days apart and the controls received one dose. Antibody titers were measured using a hemagglutination-inhibition assay on days 0, 21 and 49 after injection of the first dose. Cellular immune responses to H1N1 were determined on days 0 and 49. RESULTS: By day 21 post-vaccination, protective antibody titers of 1:32 or more were seen in 100% of controls compared to 39% of patients with B-cell malignancies (P<0.001), 46% of allogeneic stem cell transplant recipients (P<0.001) and 85% of patients with chronic myeloid leukemia (P=0.086). After a second dose, seroprotection rates increased to 68%, (P=0.008), 73%, (P=0.031), and 95% (P=0.5) in patients with B-cell malignancies, after allogeneic stem cell transplantation and with chronic myeloid leukemia, respectively. On the other hand, T-cell responses to H1N1 vaccine were not significantly different between patients and controls. CONCLUSIONS: These data demonstrate the efficacy of H1N1 vaccine in most patients with hematologic malignancies and support the recommendation for the administration of two doses of vaccine in immunocompromised patients. These results may contribute towards the development of evidence-based guidelines for influenza vaccination in such patients in the future.
Authors: Michael E Greenberg; Michael H Lai; Gunter F Hartel; Christine H Wichems; Charmaine Gittleson; Jillian Bennet; Gail Dawson; Wilson Hu; Connie Leggio; Diane Washington; Russell L Basser Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Paula Garland; Hugues de Lavallade; Takuya Sekine; Katja Hoschler; Shiranee Sriskandan; Parind Patel; Stephen Brett; Kate Stringaris; Eva Loucaides; Katherine Howe; David Marin; Ed Kanfer; Nichola Cooper; Donald Macdonald; Amin Rahemtulla; Mark Atkins; Akila Danga; Dragana Milojkovic; Ian Gabriel; Ahmad Khoder; Abdullah Alsuliman; Jane Apperley; Katayoun Rezvani Journal: Biol Blood Marrow Transplant Date: 2010-08-11 Impact factor: 5.742
Authors: Xinhui Ge; Venus Tan; Paul L Bollyky; Nathan E Standifer; Eddie A James; William W Kwok Journal: J Virol Date: 2010-01-13 Impact factor: 5.103
Authors: Elizabeth Miller; Katja Hoschler; Pia Hardelid; Elaine Stanford; Nick Andrews; Maria Zambon Journal: Lancet Date: 2010-01-21 Impact factor: 79.321
Authors: Tristan W Clark; Manish Pareek; Katja Hoschler; Helen Dillon; Karl G Nicholson; Nicola Groth; Iain Stephenson Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Hugues de Lavallade; Ahmad Khoder; Melanie Hart; Anushruti Sarvaria; Takuya Sekine; Abdullah Alsuliman; Stephan Mielke; Alexandra Bazeos; Kate Stringaris; Sara Ali; Dragana Milojkovic; Letizia Foroni; Aristeidis Chaidos; Nichola Cooper; Ian Gabriel; Jane Apperley; Sarah Belsey; Robert J Flanagan; John Goldman; Elizabeth J Shpall; Peter Kelleher; David Marin; Katayoun Rezvani Journal: Blood Date: 2013-05-29 Impact factor: 22.113
Authors: Ishac Nazi; John G Kelton; Mark Larché; Denis P Snider; Nancy M Heddle; Mark A Crowther; Richard J Cook; Alan T Tinmouth; Joy Mangel; Donald M Arnold Journal: Blood Date: 2013-07-12 Impact factor: 22.113
Authors: Vinay Rambal; Karin Müller; Chantip Dang-Heine; Arne Sattler; Mikalai Dziubianau; Benjamin Weist; Si-Hong Luu; Alexandra Stoyanova; Peter Nickel; Andreas Thiel; Avidan Neumann; Brunhilde Schweiger; Petra Reinke; Nina Babel Journal: Med Microbiol Immunol Date: 2013-09-22 Impact factor: 3.402
Authors: Abby P Douglas; Jason A Trubiano; Ian Barr; Vivian Leung; Monica A Slavin; Constantine S Tam Journal: Haematologica Date: 2017-06-28 Impact factor: 9.941
Authors: Yiqing Xu; Nanda Methuku; Praveena Coimbatore; Theresa Fitzgerald; Yiwu Huang; Ying-Yi Xiao; Murali Pagala; Shachi Gupta; William Solomon; Philip Rubin; John Treanor; Alan Astrow; Howard Minkoff; Jay S Cooper Journal: Oncologist Date: 2012-01-12